SynthesisMovement disorders : official journal of the Movement Disorder Society2017
Which ante mortem clinical features predict progressive supranuclear palsy pathology?
Synthesis in Movement disorders : official journal of the Movement Disorder Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 4 syntheses or guidelines pooled it, 161 citations in OpenAlex.
- The prevalence and incidence of progressive supranuclear palsy and corticobasal syndrome: a systematic review and meta-analysis.Journal of neurology · 2023Pooled it
- The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.Movement disorders : official journal of the Movement Disorder Society · 2022Pooled it
- Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.Movement disorders : official journal of the Movement Disorder Society · 2021Pooled it
- [Tauopathies : From molecule to therapy].Der Nervenarzt · 2018Pooled it
- Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.Nature medicine · 2021Trial
- Incident versus prevalent progressive supranuclear palsy: analyses of U.S. Alzheimer's Disease Research Centers data indicate clinical and neuropathological features of a relatively common and underrecognized tauopathy in the aging brain.Acta neuropathologica · 2026Article
- Longitudinal Cognitive Function in Progressive Supranuclear Palsy-A Review of the Evidence for Progression.Movement disorders clinical practice · 2026Review
- [4-Repeat Tauopathies: Progressive Supranuclear Palsy and Corticobasal Degeneration].Fortschritte der Neurologie-Psychiatrie · 2026Review
- Article
- Synucleinopathy-like clinical features and biologically defined synuclein seeding in PSP-Parkinsonism: an imperfect match.NPJ Parkinson's disease · 2026Article
- Cognitive impairment on the Alzheimer's Disease Centers' Uniform Data Set Version 3 Neuropsychological Test Battery in a Peruvian population with progressive supranuclear palsy.Arquivos de neuro-psiquiatria · 2026Article
- A narrative review of serum biomarkers in progressive supranuclear palsy, corticobasal syndrome, and related disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Comorbid pathologies and their impact on progressive supranuclear palsy: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Epidemiology of Progressive Supranuclear Palsy in Navarre, Spain: A Population-Based Study.European journal of neurology · 2026Observational
- Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation.Journal of neurology · 2026Article
- Progressive Supranuclear Palsy-A Global Review.Movement disorders clinical practice · 2026Review
- Article
- Progressive Supranuclear Palsy (PSP): An Orthoptic Assessment.The British and Irish orthoptic journal · 2026Review
- Review
- Early subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study.Journal of neurology · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 20 institutions in 11 countries.
Funding
Abstract
backgroundProgressive supranuclear palsy (PSP) is a neuropathologically defined disease presenting with a broad spectrum of clinical phenotypes.
objectiveTo identify clinical features and investigations that predict or exclude PSP pathology during life, aiming at an optimization of the clinical diagnostic criteria for PSP.
methodsWe performed a systematic review of the literature published since 1996 to identify clinical features and investigations that may predict or exclude PSP pathology. We then extracted standardized data from clinical charts of patients with pathologically diagnosed PSP and relevant disease controls and calculated the sensitivity, specificity, and positive predictive value of key clinical features for PSP in this cohort.
resultsOf 4166 articles identified by the database inquiry, 269 met predefined standards. The literature review identified clinical features predictive of PSP, including features of the following 4 functional domains: ocular motor dysfunction, postural instability, akinesia, and cognitive dysfunction. No biomarker or genetic feature was found reliably validated to predict definite PSP. High-quality original natural history data were available from 206 patients with pathologically diagnosed PSP and from 231 pathologically diagnosed disease controls (54 corticobasal degeneration, 51 multiple system atrophy with predominant parkinsonism, 53 Parkinson's disease, 73 behavioral variant frontotemporal dementia). We identified clinical features that predicted PSP pathology, including phenotypes other than Richardson's syndrome, with varying sensitivity and specificity.
conclusionsOur results highlight the clinical variability of PSP and the high prevalence of phenotypes other than Richardson's syndrome. The features of variant phenotypes with high specificity and sensitivity should serve to optimize clinical diagnosis of PSP. © 2017 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.